COVID-19 has now been labelled a pandemic, necessitating the development of novel medicines as we move beyond containment. All eyes are on people working on the front lines of drug development and production. There is tremendous demand to provide both urgent and long-term remedies for people who have been impacted, as well as biotherapies and vaccines to avoid future outbreaks. It is unrealistic to meet the current global crisis by developing new pharmaceuticals from the ground up because it is a lengthy procedure. Drug repurposing screens are a helpful and successful method of identifying prospective SARS-CoV-2 treatments.
Title : Extracellular vesicles as delivery vehicles of therapeutic compounds
Stefania Raimondo, University of Palermo, Italy
Title : EU GMP annex1 barrier system and PIC/s annex 2A on cell and gene therapy
Richard Denk, SKAN AG, Switzerland
Title : Role of nanoformulations in treating Cystic Fibrosis
Bhupendra Gopalbhai Prajapati, Ganpat University, India
Title : Dual GIP/GLP-1 receptor stimulation in treatment of type 2 diabetes mellitus – The ground-breaking 'twincretin' approach
Miroslav Radenkovic, University of Belgrade, Serbia
Title : Pathology and patient safety: The vital role of electronic medical record and pathology informatics in error reduction and precision medicine
Consolato M Sergi, Universities of Alberta and Ottawa, Canada
Title : mRNA-based systemically delivered directed gene therapy using nanomaterials
A C Matin, Stanford University, United States
Title : Colon-specific scallop hydrolysates/Κ-carrageenan hydrogel loaded with curcumin alleviates dss-induced colitis through modulation of inflammatory cytokines and gut microbiota
Hai Tao Wu, Dalian Polytechnic University, China
Title : Mucoadhesive electrospun fibrous systems for the fast and sustained delivery of drugs
Luis Jesus Villarreal Gomez, Autonomous University of Baja California, Mexico
Title : General and local anaesthetic agents: An analysis of their safety data
Francesca Gargano, Campus Bio-Medico University of Rome, Italy
Title : 15,16-dihydrotanshinone-I-laden PLGA-co-PEG nanoparticles are potential therapeutic agents for the treatment of colorectal cancer by targeting the β-catenin/CD36 axis
Kwan Hiu Yee, Hong Kong Baptist University, China